Aktuellt
SENASTE
Redeye leaves a short comment following Alzinova’s announcement earlier today. The company states that a new scientific article presenting preclinical results for its antibody candidate ALZ-201 has been published. The results indicate a higher specificity toward the toxic oligomeric formations of Aβ42, which is widely thought to be a main driver of Alzheimer’s disease.
LÄS MER
